- 雙方的首要合作是在中國(guó)加速開發(fā)用于治療實(shí)體腫瘤的2seventy的MAGE-A4項(xiàng)目
中國(guó)上海、美國(guó)馬薩諸塞州劍橋市，2022年10月27日 – 藥明巨諾（港交所代碼：2126），一家獨(dú)立的、專注于開發(fā)、生產(chǎn)及商業(yè)化細(xì)胞免疫治療產(chǎn)品的創(chuàng)新型生物科技公司，與2seventy bio（納斯達(dá)克代碼：TSVT），一家領(lǐng)先的免疫腫瘤細(xì)胞治療公司，今天宣布達(dá)成戰(zhàn)略合作。雙方將建立細(xì)胞治療的轉(zhuǎn)化及臨床開發(fā)平臺(tái)，在中國(guó)內(nèi)地、香港及澳門地區(qū)加速T細(xì)胞免疫治療產(chǎn)品的開發(fā)。
雙方的首要合作將圍繞2seventy的MAGE-A4 TCR項(xiàng)目，該項(xiàng)目用于治療實(shí)體腫瘤，是由2seventy與再生元（Regeneron）合作開發(fā)。MAGE-A4是癌-睪丸抗原MAGE家族的一員，這類抗原在多種實(shí)體腫瘤中均有表達(dá)。該項(xiàng)目旨在開發(fā)T細(xì)胞受體（TCR）療法，用于治療MAGE-A4陽(yáng)性的實(shí)體腫瘤。
藥明巨諾首席醫(yī)學(xué)官M(fèi)ark J. Gilbert博士表示：“我們很高興與2seventy bio攜手，在中國(guó)共同開發(fā)MAGE-A4 TCR項(xiàng)目及其他潛在的產(chǎn)品。2seventy bio是一家業(yè)界一流的細(xì)胞治療公司，擁有先進(jìn)的技術(shù)及經(jīng)驗(yàn)豐富的團(tuán)隊(duì)。此次戰(zhàn)略合作將進(jìn)一步發(fā)揮我們包括轉(zhuǎn)化研究及臨床開發(fā)在內(nèi)的、世界一流的綜合能力，我們期待加速開發(fā)更多具有突破性治療價(jià)值的細(xì)胞免疫治療產(chǎn)品，服務(wù)更多中國(guó)乃至全球的癌癥患者?！?/p>
2seventy bio首席醫(yī)學(xué)官Steve Bernstein表示：“此次合作對(duì)于患者的真正價(jià)值，在于我們?cè)鰪?qiáng)了快速測(cè)試、學(xué)習(xí)并推進(jìn)我們創(chuàng)新細(xì)胞治療項(xiàng)目的能力。藥明巨諾對(duì)于中國(guó)患者未被滿足的治療需求、中國(guó)的注冊(cè)事務(wù)流程、以及臨床開發(fā)路徑具有深入的洞察。借助此次合作機(jī)會(huì)，我們將彼此的獨(dú)特優(yōu)勢(shì)經(jīng)驗(yàn)相互結(jié)合，建立差異化的平臺(tái)，從而實(shí)現(xiàn)我們的目標(biāo)，即讓創(chuàng)新治療更快地惠及患者?！?/p>
根據(jù)協(xié)議條款，2seventy將授權(quán)藥明巨諾在中國(guó)內(nèi)地、香港及澳門地區(qū)開展MAGE-A4細(xì)胞治療項(xiàng)目的權(quán)利，藥明巨諾將負(fù)責(zé)其在中國(guó)的開發(fā)、生產(chǎn)及商業(yè)化，2seventy有權(quán)獲得里程碑付款及基于產(chǎn)品收入的特許權(quán)使用費(fèi)。此外，2seventy可將基于該合作項(xiàng)目而獲得的早期臨床數(shù)據(jù)用于在其他地區(qū)開發(fā)該產(chǎn)品。此次交易的完成尚待取得藥明巨諾股東的批準(zhǔn)，并滿足其他慣例成交條件。
# # #
關(guān)于MAGE-A4項(xiàng)目
MAGE-A4是癌-睪丸抗原MAGE家族的一員，這類抗原在多種實(shí)體腫瘤中均有表達(dá)。我們構(gòu)造了我們?cè)谂cMediGene的合作中發(fā)現(xiàn)的一種高效的TCR，該TCR可識(shí)別HLA呈遞的MAGE-A4多肽，并憑借我們CTBR12 TGF-beta“翻轉(zhuǎn)”受體技術(shù)進(jìn)一步增強(qiáng)這些T細(xì)胞的效力，將TGF-beta免疫抑制效應(yīng)轉(zhuǎn)化為T細(xì)胞的激活信號(hào)。再生元（Regeneron）和2seventy bio正共同開發(fā)該項(xiàng)目。
關(guān)于藥明巨諾
藥明巨諾（港交所代碼：2126）是一家獨(dú)立的、創(chuàng)新型的生物科技公司，專注于開發(fā)、生產(chǎn)及商業(yè)化細(xì)胞免疫治療產(chǎn)品，并致力于以創(chuàng)新為先導(dǎo)，成為細(xì)胞免疫治療引領(lǐng)者。創(chuàng)建于2016年，藥明巨諾已成功打造了國(guó)際領(lǐng)先的細(xì)胞免疫治療的綜合性產(chǎn)品開發(fā)平臺(tái)，以及涵蓋血液及實(shí)體腫瘤的細(xì)胞免疫治療產(chǎn)品管線。藥明巨諾致力于以突破性、高品質(zhì)的細(xì)胞免疫治療產(chǎn)品給中國(guó)乃至全球患者帶來治愈的希望，并引領(lǐng)中國(guó)細(xì)胞免疫治療產(chǎn)業(yè)的健康規(guī)范發(fā)展。欲了解更多詳情，請(qǐng)?jiān)L問：dudj.cn。
關(guān)于2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape.
With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.
For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: Twitter and LinkedIn.
2seventy bio is a trademark of 2seventy bio, Inc.
藥明巨諾前瞻性聲明
本發(fā)布所包含的前瞻性聲明是基于管理層現(xiàn)有的期望和信心，會(huì)存在一定的不確定性或風(fēng)險(xiǎn)從而導(dǎo)致實(shí)際結(jié)果在實(shí)質(zhì)上與所描述的有所區(qū)別。顯著的風(fēng)險(xiǎn)和不確定性，可能包括了以下涉及的內(nèi)容，以及在公司提交給香港交易所（HKEX）的報(bào)告中予以更為全面的描述。除非另有注明，公司提供截至發(fā)布日期當(dāng)日的信息，并且明確無義務(wù)更新相關(guān)事項(xiàng)及其所含內(nèi)容或提供任何解釋。具體內(nèi)容，詳見公司官網(wǎng)：dudj.cn/cn/forward-looking-statements/。
Cautionary Note Regarding Forward-Looking Statements of 2seventy bio
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development, manufacture or sale of our product candidates, including the results and expected timing of ongoing and planned clinical trials for our product candidates in China and the speed with which we can bring those candidates into clinical trials; statements about the efficacy and perceived therapeutic benefits of our product candidates and the potential indications, market opportunities and demand therefor; statements about the strategic plans for 2seventy bio and potential corporate development opportunities; statements regarding the company’s financial condition, and other future financial results; and statements about our ability to execute our strategic priorities. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation; the risk that our plans with respect to the preclinical and clinical development and regulatory approval of our product candidates may not be successfully achieved on the planned timeline, or at all. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2021, as supplemented and/or modified by our most recent Quarterly Report on Form 10-Q and any other filings that we have made or will make with the Securities and Exchange Commission in the future. All information in this press release is as of the date of the release, and 2seventy bio undertakes no duty to update this information unless required by law.